海角破解版

Annexin V Binding Buffer

Assay buffer for labeling with Annexin V

Annexin V Binding Buffer

Assay buffer for labeling with Annexin V

Catalog #
(Select a product)
Assay buffer for labeling with Annexin V
Request Pricing Request Pricing

Overview

Annexin V Binding Buffer is an isotonic buffer used in conjunction with Annexin V dyes (e.g. Catalog #100-0329) and either 7-AAD (Catalog #75001) or Propidium Iodide (Catalog #75002). This buffer contains an optimal concentration of calcium that facilitates the binding of Annexin V to phosphatidylserine on the cell surface, which is essential for the detection of early-stage cell apoptosis by flow cytometry.
Application
Flow Cytometry
Area of Interest
Immunology

Protocols and Documentation

Find supporting information and directions for use in the Product Information Sheet or explore additional protocols below.

Document Type
Product Name
Catalog #
Lot #
Language
Document Type
Product Name
Catalog #
100-0334
Lot #
All
Language
English
Document Type
Product Name
Catalog #
100-0334
Lot #
All
Language
English

Applications

Resources and Publications

Publications (1)

Clostridioides difficile toxin B subverts germinal center and antibody recall responses by stimulating a drug-treatable CXCR4-dependent mechanism. K. Norman et al. Cell reports 2024 May

Abstract

Recurrent Clostridioides difficile infection (CDI) results in significant morbidity and mortality. We previously established that CDI in mice does not protect against reinfection and is associated with poor pathogen-specific B cell memory (Bmem), recapitulating our observations with human Bmem. Here, we demonstrate that the secreted toxin TcdB2 is responsible for subversion of Bmem responses. TcdB2 from an endemic C. difficile strain delayed immunoglobulin G (IgG) class switch following vaccination, attenuated IgG recall to a vaccine booster, and prevented germinal center formation. The mechanism of TcdB2 action included increased B cell CXCR4 expression and responsiveness to its ligand CXCL12, accounting for altered cell migration and a failure of germinal center-dependent Bmem. These results were reproduced in a C. difficile infection model, and a US Food and Drug Administration (FDA)-approved CXCR4-blocking drug rescued germinal center formation. We therefore provide mechanistic insights into C. difficile-associated pathogenesis and illuminate a target for clinical intervention to limit recurrent disease.